British drugmaker AstraZeneca Plc said Ironwood Pharmaceuticals Inc would buy the US marketing rights for its newly-approved gout drug for up to $265 million.
The deal would give Ironwood the rights to sell the drug, Zurampic, which was approved in the United States last year to treat high levels of uric acid in the blood of patients suffering from gout.
AstraZeneca did not mention any upfront payment to be made by the U.S. drugmaker in its statement on Tuesday.
- (Reuters)
This article was corrected on Friday, May 6th
AstraZeneca to sell US rights for gout drug for up to $265m
Deal sees Ironwood Pharmaceuticals take on the rights to sell Zurampic
IN THIS SECTION
Ireland fail to ignite as All Blacks end three-year run of home wins
All Blacks end Ireland’s winning streak at home with deserving victory
Ireland 13 New Zealand 23: How the Irish players rated at the Aviva Stadium
Ireland 13 New Zealand 23 FT: Autumn Nations Series as it happened
Tedious scrums continue to be a blessing and a curse for Ireland
Business Today
Get the latest business news and commentary from our expert business team in your inbox every weekday morning